Navigation Links
Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months
Date:12/8/2008

SEATTLE, Dec. 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that extended follow-up data for the Zevalin(R) ([90Y]-ibritumomab tiuxetan) First-line Indolent (FIT) study presented at the American Society of Hematology (ASH) 50th Annual Meeting by Morschhauser, et al demonstrated the continued improvement in progression-free survival (PFS) following Zevalin consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieved a response to first line therapy over chemotherapy alone. Additionally, Zevalin consolidation did not adversely affect the use of various effective second-line treatments including stem cell transplants in patients who relapsed.

"The FIT study follow-on results are quite impressive when one considers that the median progression free survival for the Zevalin recipients that achieved a complete remission (CR) after induction therapy has not yet been reached with an estimated 67 months compared to 30 months with chemotherapy alone," said James A. Bianco, M.D., CEO of Cell Therapeutics. "A single dose of consolidation that could allow patients with a CR from requiring additional treatment for their NHL for over 3 years represents a significant advancement in the treatment of this disease."

The multinational, randomized phase III FIT study evaluated the benefit and safety of a single infusion of Zevalin in patients with follicular B-cell non-Hodgkin's lymphoma who had achieved a partial remission (PR) or a complete remission / complete remission unconfirmed (CR/CRu) after receiving standard first-line chemotherapy regimens. Patients were randomized to either Zevalin consolidation or no further therapy. The FIT trial results were first presented at the December 2007 ASH annual meeting. The results were subsequently published in Journal of Clinical Oncology 2008 26(32):5156-64. At the 2008 ASH meeting, the investigators prese
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
2. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
3. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
4. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
7. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... -- EU5 Capsule Endoscopy Systems Market Outlook to 2020 ... "EU5 Capsule Endoscopy Systems Market Outlook to 2020", provides ... market. The report provides value, in millions of US ... dollars) within market segments - Capsule Endoscopes, Capsule Endoscopy ... report also provides company shares and distribution shares data ...
(Date:9/29/2014)... 2014 EU5 Sigmoidoscopes Market Outlook to ... Sigmoidoscopes Market Outlook to 2020", provides key market ... provides value, in millions of US dollars, volume ... within market segments - Flexible Video Sigmoidoscopes and ... (Fibre) Sigmoidoscopes). The report also provides ...
(Date:9/29/2014)... -- Following US and European approvals of Elekta,s Versa ... Administration (CFDA) has cleared the radiation therapy system for ... to the International Agency for Research on Cancer, well ... year in China 1 , ... and esophageal cancers 2 . Versa HD is designed ...
Breaking Medicine Technology:EU5 Capsule Endoscopy Systems Market Outlook to 2020 2EU5 Capsule Endoscopy Systems Market Outlook to 2020 3EU5 Sigmoidoscopes Market Outlook to 2020 2EU5 Sigmoidoscopes Market Outlook to 2020 3Chinese clinics and cancer patients to benefit from Elekta's Versa HD radiation therapy system 2Chinese clinics and cancer patients to benefit from Elekta's Versa HD radiation therapy system 3
... 2012  Amgen (NASDAQ: AMGN ) will present at ... at the Four Seasons Hotel, Chicago, Ill., beginning at 8:20 ... Relations at Amgen, will present. Live audio of the presentation ... www.amgen.com , under Investors. About ...
... (Nasdaq: ESRX ) announced that it will present ... on May 16, 2012 at 1:00 p.m. PDT (4:00 p.m. ... Nevada. This presentation will also be broadcast via ... section of Express Scripts, web site at http://www.express-scripts.com   ...
Cached Medicine Technology:
(Date:9/30/2014)... 2014 Computer Resources of America, ... based in New York City, has been awarded ... to transform, manage, and support the IT environment ... a leading provider of innovative services that enable ... The contract will cover the four NY-metro ...
(Date:9/30/2014)... Albany, IN (PRWEB) September 30, 2014 ... Dr. Ron Receveur encourages all persons who have received ... disease in a recent blog post. , The post, ... those with dental implants that if they don’t brush ... the same way people lose their natural teeth: the ...
(Date:9/30/2014)... Ontario, Canada (PRWEB) September 30, 2014 ... diagnostic imaging services based in San Juan, Puerto ... automate their workflows. , Nivia Souffront, site ... to their facility. “We are excited to bring ... to provide better patient care and physician satisfaction ...
(Date:9/30/2014)... September 30, 2014 3M has added four ... high bond tapes. 3M 5906 , 3M 5907 ... are conformable VHBs which help create the strongest bond possible ... are used for bonding to difficult surfaces such as paints, ... 5906, 5907, 5908, and 5905 are designed specifically for electronic ...
(Date:9/30/2014)... FL (PRWEB) September 30, 2014 Doctors often ... received abnormal mammogram results. Most breast ultrasounds are done ... Center for Diagnostic Imaging in Miami . The Center ... as an alternative to MRI. Most patients find ultrasounds ... open space and do not have to remain perfectly still. ...
Breaking Medicine News(10 mins):Health News:CRA Awarded Managed Services Contract for Large NYC Nonprofit 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 3Health News:Signet Puerto Rico Leverages PowerServer RIS/PACS/PM™ to Improve Patient Care, Cut Costs 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 3Health News:Breast Ultrasounds Are a Comfortable and Convenient Option for Patients and Referring Doctors 2
... seem to be in the grips of a mumps ... officials suspect// that it spread easily to the other ... have helped spread the infection to the other states. ... diseases can spread easily through air travel. According to ...
... first heart transplant patient whose donor heart was removed ... operation was performed on the school girl, Hannah Clark, 12, ... body rejected her 10-yeat-old "piggy-back" heart, the nickname for the ... with the new one surgically attached to it. ...
... emergency services, in ten government medical college hospitals in ... mount pressure on the government in support of their ... Students Association are on an indefinite strike demanding the ... concession to the in-service doctors in admission to the ...
... that the ?6.2bn upgrade of the NHS IT system ... magazine said that the group of academics are questioning if ... saying that the plan was under a "constant review" and ... 30,000 GPs in England to almost 300 hospitals by 2012. ...
... Rajkumar (77), Kannada superstar and winner of the prestigious Dada ... hospital this afternoon. //The superstar had come in the limelight ... for more than 100 days, about six years ago, according ... of Kannada thespian Rajkumar were donated to an eye Bank, ...
... of Technology are developing a kind of lab-on-a-chip which ... //,This would benefit astronauts on long missions, who will ... to diagnose infection, allergies, anemia or deficiencies in the ... by the National Space Biomedical Research Institute (NSBRI). ...
Cached Medicine News:Health News:Donor Heart Gives Way for Patient’s Own Hear 2Health News:Technology at its nano best: hand-held lab-on-a-chip for blood tests 2
... Micro Anchor is the smallest, strongest ... flexibility in placement into even the ... with 3-0 or 4-0 ETHIBOND EXCEL ... or cutting swaged needles. The kit ...
... a threaded titanium anchor, specifically ... The anchor features wide threads ... optimize bone purchase, as well ... prevent suture binding. Fastin RC ...
The GII titanium anchor is the "Gold Standard" for soft tissue reattachment to bone. The GII's small size, high pull-out strength and wide range of clinical applications make it the anchor of choice ...
... Proxis features 'proximal protection' -- providing ... removal, even in vessels with side branches. ... to use. It does not require the ... removal of embolic debris. ,Proxis is ...
Medicine Products: